| Previous Close | 56.92 |
| Open | 56.80 |
| Bid | 55.90 x 100 |
| Ask | 56.09 x 100 |
| Day's Range | 55.85 - 56.86 |
| 52 Week Range | 46.01 - 77.12 |
| Volume | 5,476,300 |
| Avg. Volume | 8,520,434 |
| Market Cap | 92.09B |
| Beta | 0.97 |
| PE Ratio (TTM) | 19.42 |
| EPS (TTM) | 2.88 |
| Earnings Date | Jul 26, 2017 - Jul 31, 2017 |
| Dividend & Yield | 1.56 (2.75%) |
| Ex-Dividend Date | 2017-04-05 |
| 1y Target Est | 57.14 |
- Forbes•6 hours ago
A Closer Look At Bristol-Myers Squibb's Oncology Business
Cancer drugs (oncology business) account for nearly 60% of Bristol-Myers Squibb's valuation, according to our estimates. Empirically and fundamentally speaking, the stock’s performance is highly tied to clinical trial results and the uptake of the company’s new cancer drugs.
- Zacks•8 hours ago
Bristol-Myers Reports Data on Immuno-Oncology Drug Empliciti
Bristol-Myers Squibb Company (BMY) announced four-year follow-up data from the phase III study, ELOQUENT-2 on immuno-oncology Empliciti.
- Bloomberg•9 hours ago
Three Little-Noticed Wins for Corporations at the Supreme Court
Some class-action plaintiffs will have to find less-friendly courts for their lawsuits.
